- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Protagonist Therapeutics Inc (PTGX)Protagonist Therapeutics Inc stock price live, this page displays NASDAQ PTGX stock exchange data. View the PTGX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Protagonist Therapeutics Inc real time stock price chart below.
What Is the Protagonist Therapeutics Inc Stock Price Today?
The Protagonist Therapeutics Inc stock price today is 42.06.
What Is the Stock Symbol for Protagonist Therapeutics Inc?
The stock ticker symbol for Protagonist Therapeutics Inc is PTGX.
Is PTGX the Same as $PTGX?
$PTGX is a common way to refer to the Protagonist Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Protagonist Therapeutics Inc Trade On?
Protagonist Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Protagonist Therapeutics Inc a Good Stock to Buy?
Determining whether Protagonist Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Protagonist Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTGX quote. (ISIN: US74366E1029)
What Is the Protagonist Therapeutics Inc Stock Price Today?
The Protagonist Therapeutics Inc stock price today is 42.06.
What Is the Stock Symbol for Protagonist Therapeutics Inc?
The stock ticker symbol for Protagonist Therapeutics Inc is PTGX.
Is PTGX the Same as $PTGX?
$PTGX is a common way to refer to the Protagonist Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Protagonist Therapeutics Inc Trade On?
Protagonist Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Protagonist Therapeutics Inc a Good Stock to Buy?
Determining whether Protagonist Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Protagonist Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTGX quote. (ISIN: US74366E1029)
NASDAQ
Currency in USD
42.06
+0.38(+0.91%)
Closed
After Hours
42.060.00(0.00%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
41.31
42.77
52 wk Range
19.00
48.89
PTGX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
41.3142.77
52 wk Range
19.0048.89
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
PTGX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
57.50
Upside
+36.71%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Protagonist Therapeutics Inc Company Profile
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics Inc SWOT Analysis
Financial Outlook | With $595 million in cash and an average analyst price target of $45.75, Protagonist is well-positioned to fund operations through 2027 and pursue growth opportunities |
Pipeline Expansion | PN-881, a potent IL-17 antagonist, showcases Protagonist's innovation in peptide-based drugs, with plans for Phase 1 study initiation in Q4 2025 |
Strategic Partnerships | Collaborations with Takeda and Johnson & Johnson bolster Protagonist's pipeline, providing external validation and financial support for key drug candidates |
Clinical Milestones | Protagonist's rusfertide enters Phase 3 trials for polycythemia vera, with efficacy data expected in Q1 2025, potentially paving the way for market entry |
Compare PTGX to Peers and Sector
Metrics to compare | PTGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTGXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.7x | −2.1x | −0.7x | |
PEG Ratio | 0.07 | 0.03 | 0.00 | |
Price / Book | 4.7x | 1.3x | 2.6x | |
Price / LTM Sales | 7.7x | 19.5x | 3.2x | |
Upside (Analyst Target) | 37.9% | 378.3% | 47.0% | |
Fair Value Upside | Unlock | 10.0% | 7.5% | Unlock |
Analysts' Recommendations
9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 57.50
(+36.71% Upside)
People Also Watch
FAQ
What Is the Protagonist Therapeutics (PTGX) Stock Price Today?
The Protagonist Therapeutics stock price today is 42.06
What Stock Exchange Does Protagonist Therapeutics Trade On?
Protagonist Therapeutics is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Protagonist Therapeutics?
The stock symbol for Protagonist Therapeutics is "PTGX."
What Is the Protagonist Therapeutics Market Cap?
As of today, Protagonist Therapeutics market cap is 2.51B.
What is Protagonist Therapeutics Earnings Per Share?
The Protagonist Therapeutics EPS is 2.80.
What Is the Next Protagonist Therapeutics Earnings Date?
Protagonist Therapeutics will release its next earnings report on Mar 18, 2025.
From a Technical Analysis Perspective, Is PTGX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.